What is Texas Drug Court under Gov't Code Ch. 122?
Texas Drug Court under Government Code Chapter 122 is a specialty-court diversion program for drug-dependent defendants facing felony drug prosecutions. It is not a charge but a placement — a 12-24 month, four-phase program of intensive supervision, treatment, and judicial accountability that can reduce or dismiss the underlying offense and unlock art. 411.0728 non-disclosure.
- Specialty-court statutory authority — Gov't Code §§ 122.001-122.005
- Chapter 122 establishes the Texas Drug Court Program. Section 122.001 supplies definitions and program purposes; § 122.002 authorizes counties to establish programs and sets minimum design requirements (drug screening, judicial supervision, treatment, status hearings, sanctions and incentives, aftercare); § 122.003 governs program operation; § 122.004 requires program reporting to the Office of Court Administration; § 122.005 addresses funding. The chapter is a permissive enabling framework — counties choose whether to operate a program and how to structure eligibility within the statutory minimums. State v. Hill, 558 S.W.3d 280 (Tex. Crim. App. 2018), addresses post-program non-disclosure mechanics for specialty courts.
- Distinct from other Texas specialty courts
- Texas operates four parallel specialty-court frameworks under Government Code chs. 122-125, each with distinct eligibility criteria and statutory authority. Drug Court (Ch. 122) is for drug-dependent defendants. DWI Court (Ch. 123) is for repeat DWI defendants with substance dependence. Veterans Treatment Court (Ch. 124) is for veterans with service-connected substance use or mental health diagnoses. Mental Health Court (Ch. 125) is for defendants with serious mental illness driving criminal conduct. "Recovery Court" is a broader colloquial term sometimes used interchangeably or as an umbrella for several of these — but the statutory framework is keyed to the specific chapter under which the program is authorized.
- Federal funding and NADCP standards
- Federal Drug Court funding under 42 U.S.C. § 3796ii is administered through the Office of National Drug Control Policy and Bureau of Justice Assistance. Awards condition compliance with the NADCP Adult Drug Court Best Practice Standards Volume I & II — the national quality benchmark. Volume I covers participant eligibility, equity and inclusion, judicial role, incentives and sanctions, substance use disorder treatment; Volume II covers complementary treatment and social services, drug and alcohol testing, multidisciplinary team, census and caseload, monitoring and evaluation. Texas Drug Courts seeking federal funding must demonstrate adherence to these standards in their grant applications and annual reports.
- Community-supervision integration under art. 42A.301-42A.303
- Code of Criminal Procedure article 42A.301 authorizes courts to require specialty-court participation as a condition of community supervision. Article 42A.302 governs the specialty-court conditions package — drug testing, treatment compliance, status-hearing attendance, sanctions for noncompliance, aftercare. Article 42A.303 addresses program completion and the effect on the underlying community supervision. The integration means Drug Court is technically a probation condition, not a separate disposition — the defendant has been adjudicated (or deferred under art. 42A.101) and the Drug Court program runs as the controlling condition of supervision.
Drug Court is fundamentally different from the other defense work this firm does. Where the rest of the criminal-defense practice is built around suppression motions, challenges to the State's elements, jury argument, and trial advocacy, Drug Court representation is placement advocacy — convincing a multi-disciplinary screening committee that the client is the right fit for a program with limited slots, scarce resources, and high expectations. The work begins with eligibility identification (often before the client retains counsel), proceeds through clinical assessment and mitigation packaging, navigates charge-negotiation discussions calibrated to entry criteria, and continues through 12-24 months of in-program advocacy when the participant gets into trouble with sanctions, phase regression, or contemplated termination.
The strategic value is high because the outcome menu is favorable. A defendant who successfully completes a Drug Court program typically sees the underlying felony charge reduced or dismissed, can pursue non-disclosure under art. 411.0728, avoids the cascade of collateral consequences that follow a felony drug conviction (federal financial aid eligibility under 20 U.S.C. § 1091(r), housing, employment, voting in some states, licensure), and walks out of the program with documented treatment progress, employment history, and judicial recognition. The same defendant convicted on the underlying possession or delivery charge enters a five-to-ten-year window of background-check problems plus the lifetime collateral consequences of a felony drug record. The numerical asymmetry between those outcomes is what makes Drug Court placement worth fighting for.
Drug Court eligibility criteria
Texas Drug Court eligibility typically requires a felony drug charge (or charge driven by drug dependence), no violent prior, a DSM-5 substance-use-disorder diagnosis, and willingness to engage a 12-24 month program. Each program sets its own additional criteria, and prosecutor referral is generally required.
The eligibility criteria are standardized at the high level but vary materially across the four DFW programs. The threshold requirements are constant: the defendant must face a felony drug charge under Health & Safety Code chapter 481 (or, in some programs, a non-drug felony where the conduct was demonstrably driven by drug dependence — theft to support a habit, for instance); the defendant must have no violent prior (assault with bodily injury, robbery, aggravated assault, or any other offense classified as a "3g" aggravated offense or designated as violent under art. 42A.054 generally disqualifies); the defendant must have a clinically validated DSM-5 Substance Use Disorder diagnosis from a licensed evaluator; and the defendant must demonstrate willingness to engage with a 12-24 month program of intensive supervision and treatment.
Program-specific criteria diverge from there. Some Texas Drug Courts limit acceptance to first-time felony defendants. Others accept defendants with prior felony drug convictions but exclude those with prior probation revocations. Some require a U.S. citizen or legal permanent resident status for full participation (Texas law does not categorically exclude non-citizens from Drug Court, but immigration consequences complicate participation and many programs effectively exclude non-citizens through procedural mechanisms). Some require employment, school enrollment, or active job-searching status. Some accept clients with co-occurring mental health diagnoses; others refer those clients to Mental Health Court under Ch. 125. The placement advocacy work starts with confirming which program the case is eligible for and which program offers the most favorable terms for this specific client.
The prosecutor's diversion attorney is the gatekeeper. Texas Drug Courts operate by referral — almost universally, the District Attorney's Office maintains a specialty-court division (typical title: "Diversion Attorney" or "Specialty Court Attorney") that screens cases, makes initial referral decisions, and represents the State at status hearings and team meetings. The defense work involves persuading that diversion attorney that the client is the right candidate for placement. The arguments are individualized — clinical assessment data, mitigation narrative, the client's stated commitment, family support, employment history, the underlying offense context, the absence of disqualifying factors. The diversion attorney then makes a recommendation to the screening committee, which typically includes the judge, prosecutor, defense bar liaison, treatment provider, probation officer, and program coordinator.
The clinical assessment is the single most consequential pre-placement document. The DSM-5 SUD diagnosis must be made by a licensed evaluator — a Licensed Chemical Dependency Counselor (LCDC), Licensed Professional Counselor (LPC), Licensed Master Social Worker (LMSW) under supervision, or psychiatrist. The assessment should document the 11 DSM-5 criteria the client meets, grade severity (mild/moderate/severe), identify any co-occurring mental health diagnoses, and recommend the level of care needed (intensive outpatient, residential, MAT integration). A poorly drafted assessment — one that minimizes the diagnosis, fails to address co-occurring conditions, or misses the connection between the SUD and the underlying offense — can defeat an otherwise strong candidacy. Counsel routinely arranges for clients to obtain a clinical evaluation from a defense-experienced evaluator before the screening committee meeting, rather than relying on the program's in-house assessment.
Program structure four phases , MAT, and accountability
Texas Drug Courts operate on a four-phase structure totaling 12-24 months. Phase 1 is intensive supervision and treatment; Phases 2-4 step down testing frequency and hearing intensity as the participant accumulates compliance milestones. MAT is permitted and federally protected.
The four-phase model is standard across accredited NADCP-conforming programs. Phase 1 lasts 8-12 weeks and is the most intensive — multiple weekly drug tests (typically 2-3 times per week, randomized), weekly status hearings before the same judge, intensive outpatient treatment (typically 9+ hours per week of clinical contact), participation in 12-step or alternative peer-support meetings (90 in 90 is a common requirement), employment or treatment as the primary daily activity, and curfew. Participants in Phase 1 are commonly on enhanced supervision with the probation department and may be subject to electronic monitoring or check-ins multiple times per week. Sanctions for Phase 1 violations are calibrated — a positive test typically generates a same-day or next-hearing response (community service, jail nights, increased treatment intensity, or phase regression depending on the violation severity and the participant's recent track record).
Phase 2 lasts 3-6 months and represents the first step-down. Testing typically reduces to weekly or twice-weekly. Status hearings shift to biweekly. Treatment continues but may move from intensive outpatient to standard outpatient or aftercare group. Employment, education, or vocational training becomes a milestone — participants are expected to be working, in school, or actively job-searching. Recovery community engagement (sponsor, home group) typically becomes a phase advancement requirement. Sanctions for Phase 2 violations are similar to Phase 1 but with more emphasis on responsibility-building (community service, essay-writing, recovery-focused requirements) and less on incarceration as a first response.
Phase 3 lasts 3-6 months and is the longest sustained-compliance phase. Testing typically moves to weekly with random additional tests. Status hearings move to monthly. Participants work on relapse-prevention skills, restitution payments, completion of any remaining court-ordered education (Drug Offender Education, parenting, anger management as applicable), and re-establishment of family relationships or other community connections. Many programs require Phase 3 participants to begin mentoring incoming Phase 1 participants or attend alumni-program events. Phase 3 graduation requirements typically include a sustained period of negative tests, documented employment or school enrollment, and treatment provider sign-off on relapse-prevention plan completion.
Phase 4 lasts 3-6 months and is the graduation pathway. Testing typically remains weekly. Status hearings are monthly or as-needed. The focus shifts to aftercare planning — continuing-care treatment, ongoing recovery community engagement, employment stabilization, vocational or educational milestones, family reunification where applicable. Many programs require Phase 4 participants to complete a graduation project (community-service hours, recovery testimony, mentoring) and to enroll in the alumni program. Graduation itself is a public ceremony with the judge, treatment team, family, and alumni in attendance. The graduation order documents successful program completion for the underlying-case disposition (reduction, dismissal, or successful deferred completion) and starts the clock on art. 411.0728 non-disclosure eligibility.
Medication-Assisted Treatment (MAT) is permitted and is increasingly the standard of care for opioid use disorder participants. NADCP Best Practice Standards explicitly prohibit programs from requiring participants to discontinue physician-prescribed methadone, buprenorphine (Suboxone), or naltrexone (Vivitrol). Federal Drug Court funding under 42 U.S.C. § 3796ii is now conditioned on MAT access. Texas Drug Courts have moved toward MAT acceptance over the past decade, although programs vary in operational practice — some courts have integrated MAT clinics on the team, others rely on referral relationships, and a small minority have remained resistant despite federal funding pressure. Placement advocacy in opioid-related cases involves confirming the specific program's MAT policy and obtaining written commitments about medication continuation before the client commits to the placement.
Local DFW Drug Courts — Collin, Dallas, Denton, Tarrant
The DFW region operates four major Drug Court programs across Collin, Dallas, Denton, and Tarrant counties. Each has distinct eligibility criteria, judge preferences, MAT integration policies, and graduation pathways. Local relationships and current program knowledge are critical for placement advocacy.
Collin County Drug Court operates out of the Collin County District Courts complex in McKinney and serves felony drug defendants from the County's 416th, 296th, and 401st Judicial District Courts (and the criminal misdemeanor courts where the underlying conduct supports felony-equivalent intervention). The presiding judge varies year-to-year as the County rotates the specialty-court docket among the district benches. The program operates with a defined slot capacity, a structured screening committee, and tight calendar control. Eligibility criteria generally exclude prior violent offenses (including any 3g aggravated offense under art. 42A.054), prior probation revocations, and offenses involving large quantities or commercial-scale delivery. The program has historically been receptive to MAT integration where the clinical case supports it and treatment provider sign-off is documented.
Dallas County Diversion Court is the largest specialty-court operation in the DFW region and operates multiple parallel tracks — including a state-conviction-prevention track and a federal-conviction-prevention track for defendants who would otherwise be referred to federal prosecution. The Dallas County District Attorney's Office maintains a robust Diversion Programs Division with dedicated diversion attorneys, and the program has expanded over the past decade under successive DAs committed to diversion-first prosecution philosophy. Eligibility is broader than Collin's in some respects (the state-conviction-prevention track accepts defendants with prior felony drug convictions where the clinical case for placement is strong) but the volume and processing pace mean placement advocacy involves more focused mitigation packaging and more attention to the screening committee's specific criteria. MAT integration is well established and the program has on-team clinical capacity.
Tarrant County Drug Court operates out of the Tarrant County Criminal District Courts in Fort Worth. The program serves felony drug defendants from the County's Criminal District Courts 1-4 and has a defined screening committee with judge, prosecutor, defense liaison, treatment provider, and probation officer. Eligibility criteria are similar to Collin's — no prior violent offense, no prior probation revocation, documented DSM-5 SUD diagnosis, willingness to engage. The program has historically operated with somewhat tighter slot capacity than Dallas and somewhat more selective screening — placement advocacy emphasizes the specific factual fit between the client and the program criteria, including the program's informal preferences about employment status and family support at intake.
Denton County Drug Impact Program is the specialty-court framework operating out of the Denton County Criminal District Courts in Denton. The program is structured around Government Code Chapter 122 with implementation specifics tailored to Denton County's caseload and resources. Eligibility criteria, judge preferences, and screening practices are similar in structure to the other DFW programs but with local procedural variations — including specific intake-assessment requirements, treatment provider contracts, and graduation milestones. Placement advocacy in Denton requires current local knowledge — the program's operational specifics have evolved over recent years, and pre-placement counsel conversations with the screening committee are typical for serious candidates.
Each of the four programs operates within the Government Code Ch. 122 framework but exercises significant discretion in implementation. The most important practical implication is that placement advocacy is local — what convinces the Collin County screening committee may not convince Dallas's, and what works in Denton may not work in Tarrant. Effective representation requires not just understanding the statutory framework but knowing the current screening committee composition, the current judge's preferences, the current MAT integration status, the program's recent trajectory (capacity, completion rates, sanction practices), and the diversion attorney's specific lens for evaluating candidates. This is relationship work as much as legal work, and counsel without active recent program experience in the specific county is at a meaningful disadvantage.
Strategies for placement advocacy
Drug Court placement advocacy is distinct from trial defense. It involves clinical assessment packaging, mitigation narrative construction, charge-negotiation calibrated to entry criteria, screening committee preparation, and direct engagement with the prosecutor's diversion attorney.
The clinical assessment is the foundation. Counsel arranges for the client to be evaluated by a licensed evaluator (LCDC, LPC, LMSW, or psychiatrist) experienced with Drug Court placement reports — not just generic substance abuse assessments. The evaluator interviews the client, reviews collateral information (medical records, prior treatment records, family input), administers standardized instruments where appropriate (DAST-10, AUDIT, ASI, or similar), and writes a clinical report that documents the 11 DSM-5 SUD criteria the client meets, grades severity, addresses any co-occurring diagnoses, and ties the substance use disorder to the underlying offense conduct. The report should also recommend the appropriate level of care (intensive outpatient, residential, MAT integration) and provide the screening committee with the clinical basis for placement.
Mitigation packaging is the narrative work. Counsel develops a comprehensive mitigation presentation — letters of support from family, employer, religious or community figures; documentation of the client's employment history, educational achievements, and community ties; medical and treatment records that contextualize the substance use; any prior treatment attempts and outcomes; the client's own statement about why Drug Court is the right fit and what commitments the client is prepared to make. The package is calibrated to the screening committee's specific concerns — what does this committee usually worry about? Recidivism risk? Treatment readiness? Family support? Employment? The mitigation package addresses those concerns specifically rather than generically.
Charge negotiation calibrates the case to the program's entry criteria. Some programs accept only specific charges, exclude certain offense categories, or have implicit ceilings on quantity or commercial scale. Where the underlying indictment is outside the program's entry criteria, counsel negotiates with the prosecutor to amend or reduce the charge to fit the program's framework — for example, dropping a Penalty Group 1 manufacture-and-delivery indictment to a possession charge in the same penalty group, or reducing a delivery quantity to below a commercial threshold. The negotiation is usually structured around the placement: the State accepts the reduction conditioned on Drug Court placement and successful completion, with a fallback agreement reinstating the higher charge on program termination.
Screening committee preparation involves coaching the client through the committee meeting. The committee will ask about the client's substance use history, prior treatment, family support, employment, motivation for placement, and willingness to engage the four-phase structure. The client needs to demonstrate genuine ownership of the substance use disorder, realistic expectations about what 12-24 months of intensive supervision will look like, and a credible commitment to the program's requirements. Counsel prepares the client to answer specific kinds of questions, anticipate areas of committee concern, and present the client's candidacy in a way that builds committee confidence in the placement. This is preparation work, not coaching the client to mislead the committee — the goal is for the client to present authentically and effectively.
Direct engagement with the diversion attorney is the gateway. Counsel meets with the prosecutor's diversion attorney before the screening committee meeting to discuss the client's candidacy, present the clinical assessment and mitigation package, address any concerns, and negotiate the placement structure. The diversion attorney's recommendation to the screening committee carries significant weight — a strong recommendation often results in placement, and a weak or qualified recommendation usually results in rejection or conditional placement with additional requirements. The pre-meeting conversation is where counsel earns the recommendation, and it is the single most important meeting in the entire placement-advocacy process.
Outcomes graduation , reduction, dismissal, and art. 411.0728 non-disclosure
Successful Drug Court graduation can produce reduction or dismissal of the underlying charge and unlocks non-disclosure eligibility under Code of Criminal Procedure article 411.0728 — sealing the record from public databases while preserving criminal-justice-agency access.
The graduation outcome menu is the reason placement advocacy is worth the investment. The specific outcome depends on the structure under which the case was placed in Drug Court — deferred adjudication, straight community supervision, or a pre-indictment diversion agreement — and the program's graduation policy. Where the case was placed under deferred adjudication, successful program completion typically results in dismissal of the underlying charge under art. 42A.111 (the deferred-adjudication discharge mechanism). Where the case was placed under straight community supervision, successful program completion typically results in early termination under art. 42A.701 and may include a judicial clarification of the conviction status. Where the case was placed under a pre-indictment diversion agreement, successful completion typically results in non-prosecution and dismissal of the charges before any indictment is returned.
Reduction is the intermediate outcome menu — the underlying charge is reduced to a lesser offense (often a Class A or B misdemeanor where the original was a felony) and the defendant is then placed on standard probation or a deferred misdemeanor disposition. Reduction is most common where the program structure does not support a direct dismissal pathway or where the prosecutor's pre-placement agreement was structured around reduction rather than dismissal. The reduction itself is often sufficient to avoid the most significant collateral consequences of a felony drug conviction (federal financial aid disqualification, certain professional licensure restrictions, immigration consequences for non-citizens), making it a meaningful outcome even when full dismissal was not available.
Article 411.0728 non-disclosure is the post-graduation sealing pathway. Section 411.0728 of the Code of Criminal Procedure authorizes non-disclosure for defendants who successfully completed a drug court program established under Government Code Chapter 122 (or veterans treatment court under Ch. 124, mental health court under Ch. 125, or DWI court under Ch. 123). The non-disclosure order seals the records of the underlying offense from public databases including private background-check vendors, with disclosure remaining available to criminal justice agencies under the limited exceptions in art. 411.0765. The procedural mechanism parallels the general non-disclosure framework under art. 411.0735 — petition filed with the convicting court, prosecutor notice, hearing if requested, and entry of the non-disclosure order. The waiting periods may differ depending on the offense category and the specific deferred or community-supervision posture under which the case was resolved.
The non-disclosure outcome is most powerful when combined with a dismissal disposition. A defendant whose underlying felony charge was dismissed after Drug Court graduation and who then secured an art. 411.0728 non-disclosure order can lawfully answer "no" to most background-check questions about criminal history (with statutory exceptions for criminal justice employment and certain enumerated occupations), avoids the federal financial aid drug-conviction question on FAFSA, and is shielded from the most disruptive collateral consequences of the original prosecution. State v. Hill, 558 S.W.3d 280 (Tex. Crim. App. 2018), addresses the broader non-disclosure framework after deferred adjudication, and the case law informs the post-Drug-Court sealing practice.
Risks and exits — termination, sanctions, and re-arrest
Drug Court is not without risk. Termination from the program returns the defendant to the original disposition track — often a contested community-supervision revocation hearing or reactivation of an indictment. Sanctions, phase regression, and re-arrest during the program require active in-program defense.
Termination from a Drug Court program is the downside risk. A participant who is unable to maintain compliance — sustained positive tests, repeated missed hearings, failure to complete treatment, re-arrest on new charges, or other material noncompliance — is subject to termination from the program. Termination returns the defendant to the original disposition track: if the case was placed under deferred adjudication, the State can move to adjudicate guilt and impose the original sentencing range; if the case was placed under straight community supervision, the State can pursue motion to revoke and impose the original suspended sentence; if the case was placed under a pre-indictment diversion agreement, the State can indict and proceed to prosecution. The exposure on termination is significant and is one of the principal reasons placement advocacy must include realistic assessment of the client's readiness for the program.
Sanctions and phase regression are the in-program responses to lesser noncompliance. The NADCP framework requires graduated sanctions calibrated to the severity of the violation — a single positive test typically generates a same-week response (community service hours, an essay, increased treatment intensity, or curfew tightening), while a pattern of positive tests or a missed hearing generates more substantial responses (jail nights, phase regression, treatment intensity increase). Phase regression — moving the participant back from Phase 2 to Phase 1, for example — extends the program length and reverses the testing-frequency and hearing-frequency step-downs. Sanctions are intended to be corrective rather than punitive, but accumulation of sanctions can move the case toward termination.
Re-arrest during the program is the most acute defense moment. A participant who is re-arrested on a new charge while in Drug Court faces parallel exposure — the new case proceeds as an ordinary prosecution, and the Drug Court team will assess whether the re-arrest triggers termination from the program. Defense work in this posture is two-front: defending the new charge on its merits while simultaneously advocating with the Drug Court team that the new charge should not be treated as a termination trigger. The outcome depends heavily on the nature of the new charge (a new drug possession charge in the context of relapse may be treated more leniently than a violent offense or a delivery charge), the participant's overall program track record, and the team's assessment of whether the participant is still capable of program completion.
In-program defense work is part of the engagement. Counsel typically remains involved through the 12-24 month program length, attending status hearings, advocating during sanction discussions, and representing the participant at team meetings when the participant's case is being discussed. The retention structure varies — some firms charge a flat fee for placement plus an hourly or per-event fee for in-program work; others build the in-program work into the original engagement. The key practical point for clients is that Drug Court is a 12-24 month relationship with counsel, not a one-time placement intervention, and the in-program defense work is materially different from the placement advocacy that precedes it.
The exit options are not symmetric. A participant who successfully graduates exits with the favorable disposition described in the prior section. A participant who is terminated typically exits with a less favorable disposition than if the case had been resolved by plea at the outset, because the State retains the original charge and the cumulative effect of partial program completion is generally not credited at sentencing. This asymmetry is the central placement-advocacy calculus: the expected value of Drug Court is highly favorable only if the client is realistically capable of completing the program. Placement advocacy that pushes a client into a program the client cannot complete is worse than no placement at all — the original charge remains, the program failure becomes part of the record, and the negotiating leverage that existed at the outset is gone.
When to retain counsel for Drug Court placement
Drug Court placement advocacy works best when counsel is retained early — before the indictment, before the prosecutor's charging decision, and before any conversations with diversion attorneys. Early retention preserves charge-negotiation flexibility and maximizes the placement outcome menu.
The earliest retention point is pre-indictment. A client arrested on a felony drug charge but not yet indicted has the broadest range of placement options. Pre-indictment diversion agreements can be structured to avoid indictment altogether, preserving the client's record entirely. Counsel retained at this stage can engage with the District Attorney's diversion attorney before the case is presented to the grand jury, package the clinical assessment and mitigation materials, and negotiate the placement structure with maximum flexibility. The pre-indictment window is short — typically 30-90 days from arrest in most DFW counties — but it is the highest-leverage time for placement advocacy.
The next retention point is post-indictment but pre-plea. A client who has been indicted but has not yet entered a plea retains substantial flexibility — the charge can be reduced, the case can be placed in Drug Court under deferred adjudication, and the prosecutor's plea-bargaining posture is still active. Counsel retained at this stage works with the diversion attorney and the screening committee to structure the placement, often through a negotiated plea agreement that specifies the deferred-adjudication structure and the Drug Court placement as the dispositive plea terms. This is the typical retention point for many cases.
Later retention points — post-plea, mid-probation, or after a probation violation — preserve fewer options but still support placement advocacy in many cases. A client already on community supervision who is now facing a motion to revoke can sometimes negotiate a Drug Court placement as the alternative to revocation; a client who pled to deferred adjudication without Drug Court placement at the time of the plea can sometimes modify the conditions to add Drug Court participation. The flexibility is narrower than pre-plea retention, but the outcome menu still includes meaningful options.
Co-occurring mental health diagnoses, federal-court exposure, immigration status, and prior felony record are the factors that most often complicate placement decisions and require experienced counsel. A client with serious mental illness driving substance use may be a better candidate for Mental Health Court under Ch. 125 than Drug Court under Ch. 122 — and the placement decision shapes everything downstream. A client facing potential federal prosecution may benefit from Dallas County's federal-conviction-prevention diversion track but not from the standard state-court Drug Court placement. A non-citizen client faces immigration consequences from the underlying offense that may or may not be mitigated by Drug Court completion and the eventual non-disclosure order. These cases require counsel with current placement experience across the full specialty-court landscape.
The decision to pursue placement is not always the right decision. A client whose case is defensible on suppression grounds (Fourth Amendment violation, defective warrant, illegal stop) may achieve a full dismissal through motion practice without ever entering Drug Court — and the dismissal carries no in-program obligations, no risk of termination, and no need for clinical-assessment documentation. A client whose substance use disorder is mild or in remission may not benefit from a 12-24 month intensive-supervision program; the placement may be the wrong fit clinically. A client whose work or family obligations cannot accommodate the program's requirements may be set up to fail. Placement advocacy includes the honest assessment of whether placement is the right strategic choice, and counsel's job is to present the full menu of options — trial defense, suppression motion practice, ordinary plea negotiation, deferred adjudication without Drug Court, and Drug Court placement — and to help the client choose among them based on the realistic exposure assessment in this specific case.
